Faculty of Medicine and Medical Sciences, Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon.
INSPECT-LB: Institut National de Santé Publique, Epidémiologie Clinique et Toxicologie-Liban, Beirut, Lebanon.
BMC Psychiatry. 2019 Dec 27;19(1):421. doi: 10.1186/s12888-019-2406-y.
To define the development and validation of the Lebanese Insomnia Scale (LIS-18) to be used for the evaluation of insomnia in Lebanese adult patients.
A first cross-sectional study, conducted between August 2017 and April 2018, enrolled 789 participants (sample 1). A second sample was recruited in May 2018 to confirm the results obtained from the first sample.
Five factors derived from the LIS-18 scale items with an Eigenvalue over 1, explaining a total of 59.64% of the variance (Cronbach's alpha = 0.821). The first ROC curve, comparing participants with diagnosed insomnia to healthy individuals, showed that the optimal score was seen at a cutoff of 58.00, with a good sensitivity and specificity at this cutoff (93.3 and 88.4%, respectively). A second ROC curve, comparing participants taking drug medication for insomnia vs. those not taking drug, showed that the optimal score was seen at a cutoff of 52.50, with a good sensitivity and specificity at this cutoff (89.5 and 80.0%, respectively). A third ROC curve, comparing participants diagnosed by a physician or taking drug medication for insomnia and healthy control without insomnia drug, showed that the optimal score was seen at 51.50, with good sensitivity and specificity at this cutoff as well (90.0 and 78.10%, respectively). The positive predicted value (PPV) of the LIS-18 score in sample 2 was 93.3%, whereas the negative predicted value (NPV) was 88.4%.
The results demonstrate that the LIS-18 can be used in clinical practice and research to measure insomnia.
定义黎巴嫩失眠量表（LIS-18）的开发和验证，用于评估黎巴嫩成年患者的失眠症。
第一项横断面研究于 2017 年 8 月至 2018 年 4 月进行，共纳入 789 名参与者（样本 1）。第二项样本于 2018 年 5 月招募，以确认从第一项样本中获得的结果。
LIS-18 量表项目中，有 5 个因素的特征值超过 1，共解释了 59.64%的方差（Cronbach's alpha=0.821）。第一个 ROC 曲线，将患有诊断性失眠症的参与者与健康个体进行比较，表明最佳得分在截定点 58.00 处，在该截定点处具有良好的敏感性和特异性（分别为 93.3%和 88.4%）。第二个 ROC 曲线，将服用失眠药物的参与者与未服用失眠药物的参与者进行比较，表明最佳得分在截定点 52.50 处，在该截定点处具有良好的敏感性和特异性（分别为 89.5%和 80.0%）。第三个 ROC 曲线，将由医生诊断为失眠症或服用失眠症药物的参与者与无失眠症药物的健康对照组进行比较，表明最佳得分在 51.50 处，在该截定点处也具有良好的敏感性和特异性（分别为 90.0%和 78.1%）。在样本 2 中，LIS-18 评分的阳性预测值（PPV）为 93.3%，阴性预测值（NPV）为 88.4%。
结果表明，LIS-18 可用于临床实践和研究中，以衡量失眠症。
